Table 2 Characteristics at the Time of Cinacalcet initiation in Chronic Kidney Disease Patients, Stockholm, Sweden 2006–2012.
At Cinacalcet initiation (n = 435) | ||
|---|---|---|
Timing of cinacalcet initiation | Months after baseline, mean (SD) | 22.8 (17.0) |
Comorbidity before initiation | Charlson comorbidity index | 3.68 (1.9) |
New fracture before cinacalcet initiation | 18 (4.1) | |
New cardiovascular event before cinacalcet initiation | 76 (17.5) | |
Laboratory values | Parathyroid hormone, median (IQR) | 636 (436–860) |
P-Phosphate, median (IQR) | 1.8 (1.4–2.2) | |
B-Haemoglobin | 119.5 (15.1) | |
P-Albumin | 34.0 (4.3) | |
P-Calcium, median (IQR) | 2.45 (2.28–2.59) | |
Albuminuria (%) | ||
none | 30 (12.0) | |
micro | 43 (17.1) | |
macro | 178 (70.9) | |
Medication | Use of ACEi or ARB | 283 (65.1) |
Use of Beta-blocker | 284 (65.3) | |
Use of Vitamin D (active) | 316 (72.6) | |
Use of Vitamin D supplement | 14 (3.2) | |
Use of erythropoiesis stimulating agents | 212 (48.7) | |
Use of Calcium supplement | 196 (45.1) | |
Use of Phosphate binder | 316 (72.6) | |
Use of Prednisolone | 100 (23.0) | |
Renal replacement therapy (RRT) | No RRT | 109 (25.1) |
Dialysis | 272 (62.5) | |
Renal transplantation | 54 (12.4) |
